FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and can be used for treating or slowing progression of cancer in an individual. That is ensured by administering an effective amount of an antagonist of an anti-PD-L1 antibody, or an antigen-binding fragment thereof and an anti-TIGIT antibody antagonist, or an antigen-binding fragment thereof. Also disclosed is a method for reducing or inhibiting recurrence of cancer in an individual.
EFFECT: group of inventions provides reducing tumour growth and inducing tumour elimination by synergetic action of antagonists of anti-PD-L1-antibody and anti-TIGIT-antibody.
16 cl, 37 dwg, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USE | 2016 |
|
RU2817838C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS FOR USE THEREOF | 2016 |
|
RU2729379C1 |
| ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
| BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
| COMPOSITIONS FOR TREATING CANCER USING ANTAGONISTS WHICH BIND TO THE PD-1 SIGNALING PATHWAY COMPONENT AND MEK INHIBITORS | 2015 |
|
RU2733735C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
